{
    "hands_on_practices": [
        {
            "introduction": "To address health disparities, we first need a precise and objective way to measure them. This exercise introduces several fundamental metrics used in epidemiology and public health to quantify the difference in outcomes between groups. By calculating measures such as the absolute risk difference and relative risk for access to germline testing, you will develop a quantitative toolkit for describing the scale of inequity in a given scenario .",
            "id": "5027556",
            "problem": "In a community-based implementation study of germline testing for hereditary cancer genes, investigators assess access disparities between two income-defined groups of equal population size. Let the binary access indicator be $A \\in \\{0,1\\}$, where $A=1$ denotes that an individual obtained germline testing within a defined observation window. The observed uptake probabilities are $p_{H} = 0.70$ in the high-income group and $p_{L} = 0.30$ in the low-income group. Using definitions grounded in probability and variance for binary variables, compute the following measures of disparity in access:\n- Absolute risk difference (difference in probabilities) between the high-income and low-income groups.\n- Relative Risk (RR) as the ratio of access probabilities in the high-income to the low-income group.\n- Standardized Mean Difference (SMD) for $A$ across the two groups, where the standardization uses the pooled standard deviation appropriate for a binary variable and equal group sizes.\n\nRound each quantity to four significant figures. Report each as a pure number (no units, no percent sign) and give your final answer as a $1 \\times 3$ row matrix in the order $(\\text{absolute risk difference}, \\text{RR}, \\text{SMD})$.",
            "solution": "The problem statement is evaluated for validity before attempting a solution.\n\n**Step 1: Extract Givens**\n- Two income-defined groups of equal population size.\n- A binary access indicator $A \\in \\{0, 1\\}$, where $A=1$ indicates access to germline testing.\n- The probability of access in the high-income group is $p_{H} = 0.70$.\n- The probability of access in the low-income group is $p_{L} = 0.30$.\n- The required outputs are three measures of disparity:\n    1. Absolute risk difference (difference in probabilities).\n    2. Relative Risk (RR) as the ratio of probabilities.\n    3. Standardized Mean Difference (SMD) using the pooled standard deviation for a binary variable with equal group sizes.\n- Each output must be rounded to four significant figures.\n- The final answer must be a $1 \\times 3$ row matrix in the order $(\\text{absolute risk difference}, \\text{RR}, \\text{SMD})$.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem uses standard, well-defined concepts from epidemiology and biostatistics (risk difference, relative risk, standardized mean difference) in a realistic public health research context (genomic medicine access disparities). The framework is based on established statistical principles.\n- **Well-Posed:** All necessary data ($p_H$, $p_L$) and conditions (equal group sizes) are provided. The definitions for the quantities to be calculated are explicit and unambiguous. The problem is structured to yield a unique, stable solution.\n- **Objective:** The problem statement is expressed in precise, quantitative, and unbiased language.\n\n**Step 3: Verdict and Action**\nThe problem is scientifically grounded, well-posed, objective, and self-contained. It is therefore deemed **valid**. A solution will be provided.\n\nThe problem requires the calculation of three distinct measures of disparity in access to germline testing between a high-income group (H) and a low-income group (L). The access is a binary event, so the variable $A$ follows a Bernoulli distribution for each group.\n\nThe given probabilities are:\n$p_{H} = 0.70$ (probability of access in the high-income group)\n$p_{L} = 0.30$ (probability of access in the low-income group)\n\n1.  **Absolute Risk Difference (ARD)**\n    The absolute risk difference is the simple arithmetic difference between the two probabilities.\n    $$ARD = p_{H} - p_{L}$$\n    Substituting the given values:\n    $$ARD = 0.70 - 0.30 = 0.40$$\n    Rounding to four significant figures, we get $0.4000$.\n\n2.  **Relative Risk (RR)**\n    The relative risk is the ratio of the probability of the outcome in the exposed group (here, high-income) to the probability in the unexposed group (low-income).\n    $$RR = \\frac{p_{H}}{p_{L}}$$\n    Substituting the given values:\n    $$RR = \\frac{0.70}{0.30} = \\frac{7}{3} \\approx 2.3333...$$\n    Rounding to four significant figures, we get $2.333$.\n\n3.  **Standardized Mean Difference (SMD)**\n    The SMD, often denoted as Cohen's $d$, is the difference in means between two groups, divided by a pooled standard deviation. For a binary variable $A$ with success probability $p$, its mean is $\\mu = p$ and its variance is $\\sigma^2 = p(1-p)$.\n    The means for the two groups are:\n    $\\mu_{H} = p_{H} = 0.70$\n    $\\mu_{L} = p_{L} = 0.30$\n    The difference in means is $\\mu_{H} - \\mu_{L} = p_{H} - p_{L} = 0.40$.\n\n    The variances for the two groups are:\n    $\\sigma_{H}^2 = p_{H}(1 - p_{H}) = 0.70(1 - 0.70) = 0.70 \\times 0.30 = 0.21$\n    $\\sigma_{L}^2 = p_{L}(1 - p_{L}) = 0.30(1 - 0.30) = 0.30 \\times 0.70 = 0.21$\n\n    The problem specifies using the pooled standard deviation for equal group sizes ($n_H = n_L$). The formula for the pooled variance is the average of the individual group variances:\n    $$\\sigma_{pooled}^2 = \\frac{\\sigma_{H}^2 + \\sigma_{L}^2}{2}$$\n    The pooled standard deviation is the square root of this value:\n    $$\\sigma_{pooled} = \\sqrt{\\frac{\\sigma_{H}^2 + \\sigma_{L}^2}{2}}$$\n    Substituting the calculated variances:\n    $$\\sigma_{pooled} = \\sqrt{\\frac{0.21 + 0.21}{2}} = \\sqrt{\\frac{0.42}{2}} = \\sqrt{0.21}$$\n    Now, we compute the SMD:\n    $$SMD = \\frac{\\mu_{H} - \\mu_{L}}{\\sigma_{pooled}} = \\frac{p_{H} - p_{L}}{\\sigma_{pooled}}$$\n    Substituting the values:\n    $$SMD = \\frac{0.40}{\\sqrt{0.21}}$$\n    Calculating the numerical value:\n    $$SMD \\approx \\frac{0.40}{0.458257569...} \\approx 0.87287156...$$\n    Rounding to four significant figures, we get $0.8729$.\n\nThe three requested measures, rounded to four significant figures, are:\n- Absolute risk difference = $0.4000$\n- Relative Risk = $2.333$\n- Standardized Mean Difference = $0.8729$\nThese are to be presented in a $1 \\times 3$ row matrix.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.4000 & 2.333 & 0.8729 \\end{pmatrix}}$$"
        },
        {
            "introduction": "A positive result from a genetic test may seem definitive, but its true meaning depends heavily on the test's performance characteristics, which can vary across populations. This practice uses Bayes' theorem to explore how differences in test sensitivity and specificity between ancestry groups—often due to a higher rate of Variants of Uncertain Significance (VUS) in underrepresented populations—affect the post-test probability of disease . This calculation reveals how data inequity translates directly into diagnostic uncertainty at the patient level.",
            "id": "5027562",
            "problem": "A clinical gene panel is used to detect a pathogenic variant associated with a monogenic disorder. The panel outputs a binary call: “pathogenic-variant-positive” if the variant is classified as pathogenic by the laboratory pipeline, and “pathogenic-variant-negative” otherwise. Due to differences in representation within variant databases, individuals from an underrepresented ancestry experience a higher prevalence of Variant of Uncertain Significance (VUS), which affects both the probability that true pathogenic variants are correctly labeled and the probability that benign variants are incorrectly labeled. Assume the following are scientifically established base definitions and observations:\n\n- Sensitivity is defined as $P(+ \\mid D)$, the probability of a positive test given the disease.\n- Specificity is defined as $P(- \\mid \\neg D)$, the probability of a negative test given no disease.\n- Pretest risk is $P(D)$, the prior probability of disease before testing.\n- The law of total probability and Bayes’ theorem relate $P(D \\mid +)$ to $P(+ \\mid D)$, $P(+ \\mid \\neg D)$, and $P(D)$.\n\nConsider two ancestry groups who present with identical clinical features and family history, yielding the same pretest risk $P(D) = 0.05$. However, test performance differs across groups:\n\n- Group A (well represented in databases): sensitivity $0.94$, specificity $0.99$.\n- Group B (underrepresented in databases with more VUS): sensitivity $0.85$, specificity $0.97$.\n\nUsing only the core definitions above and first principles, compute the posterior probability of disease $P(D \\mid +)$ for each group when the panel returns a pathogenic-variant-positive result. Express both answers as decimal fractions, in the order Group A then Group B, and round each to four significant figures.",
            "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It is based on fundamental principles of probability theory, specifically Bayes' theorem, applied to a realistic scenario in medical genetics concerning diagnostic test performance and health disparities. All necessary parameters are provided, and the objective is clearly defined. Therefore, the problem is deemed valid and a solution will be furnished.\n\nThe objective is to compute the posterior probability of disease given a positive test result, denoted as $P(D \\mid +)$, for two distinct groups, A and B. We are given the pretest probability of disease, $P(D)$, and the test's sensitivity and specificity for each group. Let $D$ represent the event that an individual has the disease (i.e., carries the true pathogenic variant) and $\\neg D$ be the complementary event of not having the disease. Let $+$ be the event of a positive test result and $-$ be the event of a negative result.\n\nThe core relationship required for this computation is Bayes' theorem:\n$$ P(D \\mid +) = \\frac{P(+ \\mid D) P(D)}{P(+)} $$\nThe term in the numerator, $P(+ \\mid D)$, is the sensitivity of the test, which is provided for each group. The term $P(D)$ is the pretest probability, or prevalence, also given. The denominator, $P(+)$, is the total probability of receiving a positive test result. It can be calculated using the law of total probability, by summing over the mutually exclusive states of having the disease or not:\n$$ P(+) = P(+ \\mid D) P(D) + P(+ \\mid \\neg D) P(\\neg D) $$\nWe are given the specificity, which is $P(- \\mid \\neg D)$. The term $P(+ \\mid \\neg D)$ represents the false positive rate, which is the probability of a positive test in an individual without the disease. Since a test result on an individual without disease must be either positive or negative, we have the relation:\n$$ P(+ \\mid \\neg D) + P(- \\mid \\neg D) = 1 $$\nTherefore, the false positive rate can be calculated as:\n$$ P(+ \\mid \\neg D) = 1 - P(- \\mid \\neg D) = 1 - \\text{specificity} $$\nThe probability of not having the disease, $P(\\neg D)$, is simply:\n$$ P(\\neg D) = 1 - P(D) $$\nFor both groups, the pretest risk is given as $P(D) = 0.05$. Thus, for both groups, $P(\\neg D) = 1 - 0.05 = 0.95$.\n\nWe will now compute the posterior probability for each group separately.\n\n**For Group A (well-represented):**\nThe given parameters are:\n-   Sensitivity: $P_A(+ \\mid D) = 0.94$\n-   Specificity: $P_A(- \\mid \\neg D) = 0.99$\n-   Pretest risk: $P(D) = 0.05$\n\nFirst, we calculate the false positive rate for Group A:\n$$ P_A(+ \\mid \\neg D) = 1 - P_A(- \\mid \\neg D) = 1 - 0.99 = 0.01 $$\nNext, we calculate the total probability of a positive test, $P_A(+)$:\n$$ P_A(+) = P_A(+ \\mid D) P(D) + P_A(+ \\mid \\neg D) P(\\neg D) $$\n$$ P_A(+) = (0.94)(0.05) + (0.01)(0.95) $$\n$$ P_A(+) = 0.047 + 0.0095 = 0.0565 $$\nNow, we apply Bayes' theorem to find the posterior probability $P_A(D \\mid +)$:\n$$ P_A(D \\mid +) = \\frac{P_A(+ \\mid D) P(D)}{P_A(+)} = \\frac{(0.94)(0.05)}{0.0565} = \\frac{0.047}{0.0565} \\approx 0.8318584... $$\nRounding to four significant figures, the posterior probability for an individual in Group A is $0.8319$.\n\n**For Group B (underrepresented):**\nThe given parameters are:\n-   Sensitivity: $P_B(+ \\mid D) = 0.85$\n-   Specificity: $P_B(- \\mid \\neg D) = 0.97$\n-   Pretest risk: $P(D) = 0.05$\n\nFirst, we calculate the false positive rate for Group B:\n$$ P_B(+ \\mid \\neg D) = 1 - P_B(- \\mid \\neg D) = 1 - 0.97 = 0.03 $$\nNext, we calculate the total probability of a positive test, $P_B(+)$:\n$$ P_B(+) = P_B(+ \\mid D) P(D) + P_B(+ \\mid \\neg D) P(\\neg D) $$\n$$ P_B(+) = (0.85)(0.05) + (0.03)(0.95) $$\n$$ P_B(+) = 0.0425 + 0.0285 = 0.0710 $$\nNow, we apply Bayes' theorem to find the posterior probability $P_B(D \\mid +)$:\n$$ P_B(D \\mid +) = \\frac{P_B(+ \\mid D) P(D)}{P_B(+)} = \\frac{(0.85)(0.05)}{0.0710} = \\frac{0.0425}{0.0710} \\approx 0.5985915... $$\nRounding to four significant figures, the posterior probability for an individual in Group B is $0.5986$.\n\nIn summary, the posterior probability of disease given a positive test result is approximately $0.8319$ for Group A and $0.5986$ for Group B. This demonstrates that despite an identical pretest risk, the lower sensitivity and specificity of the test for the underrepresented group lead to a substantially lower confidence in a positive result, highlighting a significant health disparity driven by data biases.",
            "answer": "$$ \\boxed{\\begin{pmatrix} 0.8319 & 0.5986 \\end{pmatrix}} $$"
        },
        {
            "introduction": "The decision to implement a population-wide genomic screening program involves balancing costs and benefits, and these can differ substantially across groups. This exercise introduces the \"Number Needed to Screen\" (NNS), a key public health metric used to evaluate the efficiency of a screening intervention. By calculating how NNS changes with ancestry-specific disease penetrance, you will see how equitable and effective public health strategies must be informed by population-specific genetic data .",
            "id": "5027494",
            "problem": "A public health genomics program considers targeted screening for a well-characterized pathogenic variant associated with a single, clearly defined adverse health outcome in adults. The program is evaluating two ancestry-defined populations, denoted as ancestry $\\mathrm{A}$ and ancestry $\\mathrm{B}$. Assume that the prevalence of carriers of the pathogenic variant among individuals undergoing screening is the same in both populations and equal to $r = 2.4 \\times 10^{-3}$ carriers per person screened. The screening test perfectly identifies carriers, and every identified carrier accepts and fully adheres to a prophylactic intervention. The prophylactic intervention has constant efficacy $e$ across ancestries, defined as the proportional reduction in the probability of the adverse outcome among carriers who receive the intervention. Penetrance $p$ is defined as the probability that a carrier will experience the adverse outcome in the absence of intervention. Due to ancestry-specific modifiers and prior ascertainment bias, penetrance differs between the two ancestries: $p_{\\mathrm{A}} = 0.62$ and $p_{\\mathrm{B}} = 0.33$. The intervention efficacy is $e = 0.50$.\n\nUsing only fundamental definitions of penetrance, efficacy as proportional risk reduction, and the idea that the expected number of adverse outcomes averted per screened individual is the product of independent probabilities in this causal chain, derive how the number needed to screen (the number of individuals screened in the general population to avert one adverse outcome) depends on $r$, $p$, and $e$. Then, quantify how differing penetrance estimates by ancestry affect the number needed to screen by calculating the fold-change $F$ defined as $F = \\mathrm{NNS}_{\\mathrm{B}} / \\mathrm{NNS}_{\\mathrm{A}}$.\n\nReport $F$ as a pure number without units, and round your final numeric answer to four significant figures.",
            "solution": "The problem requires the derivation of a formula for the Number Needed to Screen ($\\mathrm{NNS}$) and its application to compare screening program efficiency in two populations with different penetrance values for a pathogenic variant.\n\nFirst, I will validate the problem statement.\n\n**Step 1: Extract Givens**\n- Two ancestry-defined populations: ancestry $\\mathrm{A}$ and ancestry $\\mathrm{B}$.\n- Prevalence of carriers: $r = 2.4 \\times 10^{-3}$ carriers per person screened. This is constant for both populations.\n- Screening test performance: perfect identification of carriers (sensitivity = $1$, specificity = $1$).\n- Intervention adherence: perfect. Every identified carrier accepts and adheres.\n- Intervention efficacy, $e$: proportional reduction in the probability of the adverse outcome. $e$ is constant across ancestries.\n- Penetrance, $p$: probability a carrier experiences the adverse outcome without intervention.\n- Penetrance in ancestry $\\mathrm{A}$: $p_{\\mathrm{A}} = 0.62$.\n- Penetrance in ancestry $\\mathrm{B}$: $p_{\\mathrm{B}} = 0.33$.\n- Intervention efficacy value: $e = 0.50$.\n- Definition of fold-change: $F = \\mathrm{NNS}_{\\mathrm{B}} / \\mathrm{NNS}_{\\mathrm{A}}$.\n- Required precision: Round final numeric answer to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using standard concepts from public health genomics and epidemiology such as penetrance ($p$), carrier prevalence ($r$), intervention efficacy ($e$), and number needed to screen ($\\mathrm{NNS}$). The provided values for these parameters are within a realistic range for certain monogenic disorders. The problem is well-posed, providing all necessary definitions and data to derive the requested formula and calculate the final value. It is objective and free of ambiguity. The simplifying assumptions of perfect screening and adherence are common in theoretical models to isolate the effect of specific parameters, in this case, penetrance. The problem does not violate any fundamental principles and is fully formalizable.\n\n**Step 3: Verdict and Action**\nThe problem is valid. I will proceed with the solution.\n\nThe primary task is to derive an expression for the Number Needed to Screen ($\\mathrm{NNS}$). The $\\mathrm{NNS}$ is defined as the number of individuals that must be screened to prevent one adverse outcome. This is the reciprocal of the total risk reduction per individual screened. Let us denote the number of adverse outcomes averted per person screened as $\\mathrm{OAP}$.\n\nThe derivation follows a causal pathway, as suggested by the problem statement. For a single individual selected from the general population for screening:\n1.  The probability that this individual is a carrier of the pathogenic variant is the prevalence, $r$.\n2.  Given that the individual is a carrier, the screening test will identify them with a probability of $1$, as the test is perfect.\n3.  Given that the carrier is identified, they will receive a prophylactic intervention with a probability of $1$, due to perfect acceptance and adherence.\n4.  For a carrier who receives the intervention, we must calculate the reduction in the probability of the adverse outcome.\n    - The baseline probability of the outcome for a carrier (without intervention) is the penetrance, $p$.\n    - The intervention efficacy, $e$, is defined as the *proportional* reduction in this risk. Therefore, the absolute reduction in risk for a treated carrier is $p \\times e$.\n\nThe quantity $\\mathrm{OAP}$ is the expected number of outcomes averted per person screened. This is the product of the probabilities of the independent events in the causal chain:\n(Probability of being a carrier) $\\times$ (Probability of outcome being averted for a treated carrier)\n$$\n\\mathrm{OAP} = r \\times (p \\times e) = rpe\n$$\nThe Number Needed to Screen is the reciprocal of this value:\n$$\n\\mathrm{NNS} = \\frac{1}{\\mathrm{OAP}} = \\frac{1}{rpe}\n$$\nThis is the general formula for $\\mathrm{NNS}$ based on the parameters $r$, $p$, and $e$.\n\nNext, we must calculate the fold-change $F = \\mathrm{NNS}_{\\mathrm{B}} / \\mathrm{NNS}_{\\mathrm{A}}$. Using the derived formula, we can express the $\\mathrm{NNS}$ for each ancestry:\nFor ancestry $\\mathrm{A}$:\n$$\n\\mathrm{NNS}_{\\mathrm{A}} = \\frac{1}{r \\cdot p_{\\mathrm{A}} \\cdot e}\n$$\nFor ancestry $\\mathrm{B}$:\n$$\n\\mathrm{NNS}_{\\mathrm{B}} = \\frac{1}{r \\cdot p_{\\mathrm{B}} \\cdot e}\n$$\nThe problem states that the carrier prevalence $r$ and the intervention efficacy $e$ are the same for both populations. The only differing parameter is the penetrance, $p$. We can now compute the fold-change $F$:\n$$\nF = \\frac{\\mathrm{NNS}_{\\mathrm{B}}}{\\mathrm{NNS}_{\\mathrm{A}}} = \\frac{\\frac{1}{r p_{\\mathrm{B}} e}}{\\frac{1}{r p_{\\mathrm{A}} e}}\n$$\nBy simplifying the compound fraction, we get:\n$$\nF = \\frac{r p_{\\mathrm{A}} e}{r p_{\\mathrm{B}} e}\n$$\nThe terms $r$ and $e$ cancel out, leaving a simple ratio of the penetrances:\n$$\nF = \\frac{p_{\\mathrm{A}}}{p_{\\mathrm{B}}}\n$$\nThis result shows that, under the given model, the relative efficiency of screening between the two populations is inversely proportional to their respective penetrances. A lower penetrance leads to a higher $\\mathrm{NNS}$, meaning more people must be screened to avert a single adverse event.\n\nFinally, we substitute the given numerical values for penetrance to calculate $F$:\n$p_{\\mathrm{A}} = 0.62$\n$p_{\\mathrm{B}} = 0.33$\n$$\nF = \\frac{0.62}{0.33}\n$$\n$$\nF \\approx 1.878787...\n$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\nF = 1.879\n$$\nThis means that approximately $1.879$ times more individuals must be screened in ancestry group $\\mathrm{B}$ to avert one adverse outcome compared to ancestry group $\\mathrm{A}$, due solely to the lower penetrance of the pathogenic variant in group $\\mathrm{B}$.",
            "answer": "$$\n\\boxed{1.879}\n$$"
        }
    ]
}